SEARCH

SEARCH BY CITATION

References

  • 1
    Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155162.
  • 2
    Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis inducing ligand in vivo. Nat Med 1999; 5: 157163.
  • 3
    Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165: 28862894.
  • 4
    Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002; 9: 164172.
  • 5
    Lee J, Hampl M, Albert P, Fine HA. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002; 4: 312323.
  • 6
    Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001; 4: 257266.
  • 7
    Kagawa S, He C, Gu J, Koch P, Rha S-J, Roth JA, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 51: 33303338.
  • 8
    Schenk M, Weiss TS, Gregor M, Bitzer M. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003; 63: 23692372.
  • 9
    Ma H, Liu YX, Liu SL, Kung H-F, Sun XY, Zheng DX, et al. RAAV-mediated TRAIL gene therapy suppresses liver metastatic tumor. Int J Cancer 2005; 116: 314321.
  • 10
    During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med 1998; 10: 11311135.
  • 11
    Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ, et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563567.
  • 12
    Xu R, Sun X, Chan D, Tse LY, Xu S, Xiao W, et al., Long-term expression of angiostatin suppresses metastatic liver cancer in mice. HEPATOLOGY 2003; 6: 14511460.
  • 13
    Ma H, Liu YX, Liu SL, Xu R, Zheng DX. Expression of the TRAIL114-281 mediated by adenoassociated virus and its tumoricidal activity. Chin J Med 2004; 84: 16351641.
  • 14
    Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA, et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002; 62: 36203625.
  • 15
    Mohr A, Henderson G, Dudus L, Herr I, Kuerschner T, Debatin K-M, et al. AAV-encoded expression of TRAIL in experimantal human colorectal cancer leads to tumor regression. Gene Ther 2004; 11: 534543.
  • 16
    Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95: 777783.
  • 17
    Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004; 52: 821831.
  • 18
    Guo BC, Xu YH. Anti-human hepatocellular carcinoma effects of tumor necrosis factor-related apoptosis-inducing ligand in vivo and in vitro. Acta Pharmacol Sin 2002; 9: 831836.
  • 19
    Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. HEPATOLOGY 2000; 32: 482490.
  • 20
    Kim Y, Schwabe RF, Qian T, Lemasters JJ, Brenner DA. TRAIL-mediated apoptosis requires NF-κB inhibition and the mitochondrial permeability transition in human hepatoma cells. HEPATOLOGY 2002; 36: 14981508.
  • 21
    Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, et al. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 2004; 23: 78847895.
  • 22
    Jacob D, Schumacher G, Bahra M, Davis J, Zhu HB, Zhang LD, et al. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human heptocellular carcinoma cells. World J Gastroenterol 2005; 17: 25522556.
  • 23
    Chen XP, He SQ, Wang HP, Zhao YZ, Zhang WG. Expression of TNF-related apoptosis-inducing ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. World J Gastroenterol 2003; 11: 24332440.
  • 24
    Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 27472753.
  • 25
    Trabzuni D, Famulski KS, Ahmad M. Functional analysis of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem J 2000; 350: 505510.
  • 26
    Yoon SK, Armentano D, Wands JR, Mohr L. Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice. Cancer Gen Ther 2001; 8: 573579.
  • 27
    Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 5865.
  • 28
    Yamashita Y, Shimada M, Tanaka S, Okamamoto M, Miyazaki J, Sugimachi K. Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) gene therapy for hepatocellular carcinoma. Hum Gen Ther 2002; 13: 275286.